Holding(s) in Company

RNS Number : 5107C
Hikma Pharmaceuticals Plc
01 May 2012
 



 

Notification of major interests in shares

 

LONDON, 1 May 2012 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

 

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

 

 

 

2

Reason for the notification



An acquisition or disposal of voting rights

Yes


An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached

No


An event changing the breakdown of voting rights

No


Other (please specify): Compliance with the Transparency Directive

No

 

 

3

Full name of the person subject to the notification obligation

Sectoral Asset Management Inc. (SAM)

4

Full name of shareholders

SAM acts as investment advisors/sub investment advisors to a large number of institutional clients globally. The actual shareholders are those institutional clients, some of whom have delegated voting authority to SAM.

5

Date of the Transaction (and date on which the threshold crossed is reached differently)

27 April 2012

6

Date on which the issuer notified

1 May 2012

7

Threshold that is crossed

4%

8

Notified details:


A. Voting rights attached to shares

Class type of shares (if possible using the ISIN code)

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of shares

Number of voting rights

Number of shares

Number of voting rights

% of voting rights

Direct

Indirect

Direct

Indirect

Direct

Indirect

Ordinary Shares (0.10 GBP)

GB00B0LCW083

7,922,976

2,967,495 with SAM

 

 

4,955,481 with clients

8,301,483

0

2,967,495 with SAM

 

 

5,333,988 with clients

0

1.52% with SAM

 

2.72% with clients

0%

 

B. Qualifying Financial instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights that may be acquired if the instrument if exercised/converted

% of voting rights

-

-

-

-

-

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise Price

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights instrument refers to

% of voting rights

Nominal           

Delta

-

-

-

-

-

-

-

 

Total A+B+C

Number of Voting rights

% of voting rights

2,967,495 with SAM

 

5,333,988 with clients

1.52% with SAM

 

2.72% with clients

 

9

Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable


Sectoral Asset Management Inc (SAM) act as investment advisors to clients who hold Hikma shares. Some of those clients have delegated their voting authority to SAM, while other SAM clients have retained their voting authority. The beneficial owners of the Hikma shares are SAM clients.

 

Proxy Voting

10

Name of the proxy holder

Sectoral Asset Management Inc (SAM) in respect of 1.52% of Hikma shares

11

Number of voting rights proxy holder will cease to hold

N/A

12

Date on which proxy holder will cease to hold voting rights

N/A

 

13

Additional Information


14

Contact name:

Peter Speirs, Company Secretary

15

Contact telephone number:

020 7399 2772

 

- ENDS -



About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and nonbranded generic and inlicensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUASSRUWAVRAR
UK 100

Latest directors dealings